Search Results - "John, B. A."

Adoptive cellular therapies: the current landscape by Rohaan, Maartje W., Wilgenhof, Sofie, Haanen, John B. A. G.

“…For many cancer types, the immune system plays an essential role in their development and growth. Based on these rather novel insights, immunotherapeutic…”
Get full text

Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers by Scheper, Wouter, Kelderman, Sander, Fanchi, Lorenzo F., Linnemann, Carsten, Bendle, Gavin, de Rooij, Marije A. J., Hirt, Christian, Mezzadra, Riccardo, Slagter, Maarten, Dijkstra, Krijn, Kluin, Roelof J. C., Snaebjornsson, Petur, Milne, Katy, Nelson, Brad H., Zijlmans, Henry, Kenter, Gemma, Voest, Emile E., Haanen, John B. A. G., Schumacher, Ton N.

“…Infiltration of human cancers by T cells is generally interpreted as a sign of immune recognition, and there is a growing effort to reactivate dysfunctional T…”
Get full text

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial by Voorwerk, Leonie, Slagter, Maarten, Horlings, Hugo M., Sikorska, Karolina, van de Vijver, Koen K., de Maaker, Michiel, Nederlof, Iris, Kluin, Roelof J. C., Warren, Sarah, Ong, SuFey, Wiersma, Terry G., Russell, Nicola S., Lalezari, Ferry, Schouten, Philip C., Bakker, Noor A. M., Ketelaars, Steven L. C., Peters, Dennis, Lange, Charlotte A. H., van Werkhoven, Erik, van Tinteren, Harm, Mandjes, Ingrid A. M., Kemper, Inge, Onderwater, Suzanne, Chalabi, Myriam, Wilgenhof, Sofie, Haanen, John B. A. G., Salgado, Roberto, de Visser, Karin E., Sonke, Gabe S., Wessels, Lodewyk F. A., Linn, Sabine C., Schumacher, Ton N., Blank, Christian U., Kok, Marleen

“…The efficacy of programmed cell death protein 1 (PD-1) blockade in metastatic triple-negative breast cancer (TNBC) is low 1 – 5 , highlighting a need for…”
Get full text

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma by Vos, Joris L., Elbers, Joris B. W., Krijgsman, Oscar, Traets, Joleen J. H., Qiao, Xiaohang, van der Leun, Anne M., Lubeck, Yoni, Seignette, Iris M., Smit, Laura A., Willems, Stefan M., van den Brekel, Michiel W. M., Dirven, Richard, Baris Karakullukcu, M., Karssemakers, Luc, Klop, W. Martin C., Lohuis, Peter J. F. M., Schreuder, Willem H., Smeele, Ludi E., van der Velden, Lilly-Ann, Bing Tan, I., Onderwater, Suzanne, Jasperse, Bas, Vogel, Wouter V., Al-Mamgani, Abrahim, Keijser, Astrid, van der Noort, Vincent, Broeks, Annegien, Hooijberg, Erik, Peeper, Daniel S., Schumacher, Ton N., Blank, Christian U., de Boer, Jan Paul, Haanen, John B. A. G., Zuur, Charlotte L.

“…Surgery for locoregionally advanced head and neck squamous cell carcinoma (HNSCC) results in 30‒50% five-year overall survival. In IMCISION (NCT03003637), a…”
Get full text

Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option by Rohaan, Maartje W, van den Berg, Joost H, Kvistborg, Pia, Haanen, John B A G

“…The treatment of metastatic melanoma patients with autologous tumor-infiltrating lymphocytes (TIL) shows robust, reproducible, clinical responses in clinical…”
Get full text

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma by Blank, Christian U., Rozeman, Elisa A., Fanchi, Lorenzo F., Sikorska, Karolina, van de Wiel, Bart, Kvistborg, Pia, Krijgsman, Oscar, van den Braber, Marlous, Philips, Daisy, Broeks, Annegien, van Thienen, Johannes V., Mallo, Henk A., Adriaansz, Sandra, ter Meulen, Sylvia, Pronk, Loes M., Grijpink-Ongering, Lindsay G., Bruining, Annemarie, Gittelman, Rachel M., Warren, Sarah, van Tinteren, Harm, Peeper, Daniel S., Haanen, John B. A. G., van Akkooi, Alexander C. J., Schumacher, Ton N.

“…Adjuvant ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) both improve relapse-free survival of stage III melanoma patients 1 , 2 . In stage IV disease, the…”
Get full text

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors by Kostine, Marie, Finckh, Axel, Bingham, Clifton O, Visser, Karen, Leipe, Jan, Schulze-Koops, Hendrik, Choy, Ernest H, Benesova, Karolina, Radstake, Timothy R D J, Cope, Andrew P, Lambotte, Olivier, Gottenberg, Jacques-Eric, Allenbach, Yves, Visser, Marianne, Rusthoven, Cindy, Thomasen, Lone, Jamal, Shahin, Marabelle, Aurélien, Larkin, James, Haanen, John B A G, Calabrese, Leonard H, Mariette, Xavier, Schaeverbeke, Thierry

“…Rheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs)…”
Get more information

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial by Reijers, Irene L. M., Menzies, Alexander M., van Akkooi, Alexander C. J., Versluis, Judith M., van den Heuvel, Noëlle M. J., Saw, Robyn P. M., Pennington, Thomas E., Kapiteijn, Ellen, van der Veldt, Astrid A. M., Suijkerbuijk, Karijn P. M., Hospers, Geke A. P., Rozeman, Elisa A., Klop, Willem M. C., van Houdt, Winan J., Sikorska, Karolina, van der Hage, Jos A., Grünhagen, Dirk J., Wouters, Michel W., Witkamp, Arjen J., Zuur, Charlotte L., Lijnsvelt, Judith M., Torres Acosta, Alejandro, Grijpink-Ongering, Lindsay G., Gonzalez, Maria, Jóźwiak, Katarzyna, Bierman, Carolien, Shannon, Kerwin F., Ch’ng, Sydney, Colebatch, Andrew J., Spillane, Andrew J., Haanen, John B. A. G., Rawson, Robert V., van de Wiel, Bart A., van de Poll-Franse, Lonneke V., Scolyer, Richard A., Boekhout, Annelies H., Long, Georgina V., Blank, Christian U.

“…Neoadjuvant ipilimumab and nivolumab induces high pathologic response rates (pRRs) in clinical stage III nodal melanoma, and pathologic response is strongly…”
Get full text

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial by Long, Georgina V, MD, Stroyakovskiy, Daniil, MD, Gogas, Helen, MD, Levchenko, Evgeny, MD, de Braud, Filippo, MD, Larkin, James, FRCP, Garbe, Claus, Prof, Jouary, Thomas, MD, Hauschild, Axel, Prof, Grob, Jean-Jacques, Prof, Chiarion-Sileni, Vanna, MD, Lebbe, Celeste, Prof, Mandalà, Mario, MD, Millward, Michael, Prof, Arance, Ana, MD, Bondarenko, Igor, Prof, Haanen, John B A G, Prof, Hansson, Johan, Prof, Utikal, Jochen, Prof, Ferraresi, Virginia, MD, Kovalenko, Nadezhda, Prof, Mohr, Peter, MD, Probachai, Volodymr, MD, Schadendorf, Dirk, Prof, Nathan, Paul, MD, Robert, Caroline, MD, Ribas, Antoni, Prof, DeMarini, Douglas J, PhD, Irani, Jhangir G, MA, Swann, Suzanne, PhD, Legos, Jeffrey J, PhD, Jin, Fan, MD, Mookerjee, Bijoyesh, MD, Flaherty, Keith, MD

“…Summary Background Previously, a study of ours showed that the combination of dabrafenib and trametinib improves progression-free survival compared with…”
Get full text

Immunotherapy for cancer treatment during pregnancy by Borgers, Jessica S W, Heimovaara, Joosje H, Cardonick, Elyce, Dierickx, Daan, Lambertini, Matteo, Haanen, John B A G, Amant, Frédéric

“…Immunotherapy has greatly improved outcomes for subgroups of patients with cancer. As indications keep expanding, there is an unmet need to gain a better…”
Get full text

mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial by Oosting, Sjoukje F, van der Veldt, Astrid A M, GeurtsvanKessel, Corine H, Fehrmann, Rudolf S N, van Binnendijk, Rob S, Dingemans, Anne-Marie C, Smit, Egbert F, Hiltermann, T Jeroen N, den Hartog, Gerco, Jalving, Mathilda, Westphal, Tatjana T, Bhattacharya, Arkajyoti, van der Heiden, Marieke, Rimmelzwaan, Guus F, Kvistborg, Pia, Blank, Christian U, Koopmans, Marion P G, Huckriede, Anke L W, van Els, Cecile A C M, Rots, Nynke Y, van Baarle, Debbie, Haanen, John B A G, de Vries, Elisabeth G E

“…Patients with cancer have an increased risk of complications from SARS-CoV-2 infection. Vaccination to prevent COVID-19 is recommended, but data on the…”
Get full text

Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma by Klobuch, Sebastian, Seijkens, Tom T. P., Schumacher, Ton N., Haanen, John B. A. G.

“…Immunotherapy with immune-checkpoint inhibitors (ICIs) and targeted therapy with BRAF and MEK inhibitors have revolutionized the treatment of melanoma over the…”
Get full text

Cancer immunotherapy – revisited by Punt, Cornelis J. A, Lesterhuis, W. Joost, Haanen, John B. A. G

“…Key Points Clinical development of immunotherapy has been hampered by the complexity of defining the optimal dose and schedule, and the lack of financial…”
Get full text

Tissue-resident memory CD8⁺ T cells continuously patrol skin epithelia to quickly recognize local antigen by Ariotti, Silvia, Beltman, Joost B, Chodaczek, Grzegorz, Hoekstra, Mirjam E, van Beek, Anna E, Gomez-Eerland, Raquel, Ritsma, Laila, van Rheenen, Jacco, Marée, Athanasius F. M, Zal, Tomasz, de Boer, Rob J, Haanen, John B. A. G, Schumacher, Ton N

“…Recent work has demonstrated that following the clearance of infection a stable population of memory T cells remains present in peripheral organs and…”
Get full text

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy by Logtenberg, Meike E. W., Jansen, J. H. Marco, Raaben, Matthijs, Toebes, Mireille, Franke, Katka, Brandsma, Arianne M., Matlung, Hanke L., Fauster, Astrid, Gomez-Eerland, Raquel, Bakker, Noor A. M., van der Schot, Simone, Marijt, Koen A., Verdoes, Martijn, Haanen, John B. A. G., van den Berg, Joost H., Neefjes, Jacques, van den Berg, Timo K., Brummelkamp, Thijn R., Leusen, Jeanette H. W., Scheeren, Ferenc A., Schumacher, Ton N.

“…Cancer cells can evade immune surveillance through the expression of inhibitory ligands that bind their cognate receptors on immune effector cells. Expression…”
Get full text

Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives by Rozeman, Elisa A., Dekker, Tim J. A., Haanen, John B. A. G., Blank, Christian U.

“…Malignant melanoma accounts for the highest number of deaths from skin cancer, and the prognosis of patients with stage IV disease has historically been poor…”
Get full text

Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens by Cattaneo, Chiara M., Battaglia, Thomas, Urbanus, Jos, Moravec, Ziva, Voogd, Rhianne, de Groot, Rosa, Hartemink, Koen J., Haanen, John B. A. G., Voest, Emile E., Schumacher, Ton N., Scheper, Wouter

“…Cancer neoantigens that arise from tumor mutations are drivers of tumor-specific T cell responses, but identification of T cell-recognized neoantigens in…”
Get full text

Reliability and performance of commercial RNA and DNA extraction kits for FFPE tissue cores by Patel, Palak G, Selvarajah, Shamini, Guérard, Karl-Philippe, Bartlett, John M S, Lapointe, Jacques, Berman, David M, Okello, John B A, Park, Paul C

“…Cancer biomarker studies often require nucleic acid extraction from limited amounts of formalin-fixed, paraffin-embedded (FFPE) tissues, such as histologic…”
Get full text

The Cardiac Genome Clinic: implementing genome sequencing in pediatric heart disease by Reuter, Miriam S., Chaturvedi, Rajiv R., Liston, Eriskay, Manshaei, Roozbeh, Aul, Ritu B., Bowdin, Sarah, Cohn, Iris, Curtis, Meredith, Dhir, Priya, Hayeems, Robin Z., Hosseini, S. Mohsen, Khan, Reem, Ly, Linh G., Marshall, Christian R., Mertens, Luc, Okello, John B. A., Pereira, Sergio L., Raajkumar, Akshaya, Seed, Mike, Thiruvahindrapuram, Bhooma, Scherer, Stephen W., Kim, Raymond H., Jobling, Rebekah K.

“…Purpose This study investigated the diagnostic utility of nontargeted genomic testing in patients with pediatric heart disease. Methods We analyzed genome…”
Get full text

Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma by Guislain, Aurelie, Gadiot, Jules, Kaiser, Andrew, Jordanova, Ekaterina S., Broeks, Annegien, Sanders, Joyce, van Boven, Hester, de Gruijl, Tanja D., Haanen, John B. A. G., Bex, Axel, Blank, Christian U.

“…Targeted therapy with sunitinib, pazopanib or everolimus has improved treatment outcome for patients with metastatic renal cell carcinoma patients (RCC)…”
Get full text